Matches in SemOpenAlex for { <https://semopenalex.org/work/W1519270045> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W1519270045 endingPage "7" @default.
- W1519270045 startingPage "935" @default.
- W1519270045 abstract "1. Angiotensin II (AII) acts as a potent pressor agent directly, by virtue of its vasoconstrictor activity and indirectly, by the volume expansion resulting from stimulation of aldosterone release from the adrenal cortex, leading to sodium and water retention. Various approaches of interfering with the enzymatic cascade leading to the production of AII have been made in an attempt to define therapeutic agents for the control of hypertension and heart failure. 2. AII receptor antagonists, to date, lack oral activity and have a relatively short duration of action, limiting their clinical usefulness. Inhibitors of angiotensin converting enzyme block AII production, are orally active and have been used successfully in the control of hypertension and in the treatment of congestive heart failure. 3. An ideal approach to the blockade of the renin-angiotensin system (RAS) is the inhibition of renin, an enzyme with only one known substrate (angiotensinogen) which catalyzes the first and rate-limiting step in the RAS. Early attempts to discover a renin inhibitor focused on immunologic inhibitors of renin, fragments of the prorenin sequence and compounds related to pepstatin, a potent pentapeptide inhibitor of pepsin and less potent inhibitor of renin. None of these approaches proved feasible for a variety of reasons including poor absorption, short duration of action and weak activity. 4. Substrate analogs offer the greatest promise for clinically useful renin inhibitors. Most recently, synthesis of compounds mimicking the enzyme transition state, the condition of greatest binding affinity, has resulted in renin inhibitors with potencies in the nanomolar range, which have shown hypotensive activity. These compounds contain at least one peptide bond and have limited oral activity.(ABSTRACT TRUNCATED AT 250 WORDS)" @default.
- W1519270045 created "2016-06-24" @default.
- W1519270045 creator A5090169686 @default.
- W1519270045 date "1989-08-01" @default.
- W1519270045 modified "2023-09-23" @default.
- W1519270045 title "History and philosophy of Bayer pharmaceutical research." @default.
- W1519270045 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2684180" @default.
- W1519270045 hasPublicationYear "1989" @default.
- W1519270045 type Work @default.
- W1519270045 sameAs 1519270045 @default.
- W1519270045 citedByCount "7" @default.
- W1519270045 countsByYear W15192700452017 @default.
- W1519270045 countsByYear W15192700452018 @default.
- W1519270045 crossrefType "journal-article" @default.
- W1519270045 hasAuthorship W1519270045A5090169686 @default.
- W1519270045 hasConcept C126322002 @default.
- W1519270045 hasConcept C134018914 @default.
- W1519270045 hasConcept C138976137 @default.
- W1519270045 hasConcept C180000673 @default.
- W1519270045 hasConcept C181199279 @default.
- W1519270045 hasConcept C185592680 @default.
- W1519270045 hasConcept C198710026 @default.
- W1519270045 hasConcept C2776350231 @default.
- W1519270045 hasConcept C2776714187 @default.
- W1519270045 hasConcept C2776823063 @default.
- W1519270045 hasConcept C2777425892 @default.
- W1519270045 hasConcept C2778525890 @default.
- W1519270045 hasConcept C2779281246 @default.
- W1519270045 hasConcept C45197812 @default.
- W1519270045 hasConcept C55493867 @default.
- W1519270045 hasConcept C71240020 @default.
- W1519270045 hasConcept C71924100 @default.
- W1519270045 hasConcept C84393581 @default.
- W1519270045 hasConcept C98274493 @default.
- W1519270045 hasConceptScore W1519270045C126322002 @default.
- W1519270045 hasConceptScore W1519270045C134018914 @default.
- W1519270045 hasConceptScore W1519270045C138976137 @default.
- W1519270045 hasConceptScore W1519270045C180000673 @default.
- W1519270045 hasConceptScore W1519270045C181199279 @default.
- W1519270045 hasConceptScore W1519270045C185592680 @default.
- W1519270045 hasConceptScore W1519270045C198710026 @default.
- W1519270045 hasConceptScore W1519270045C2776350231 @default.
- W1519270045 hasConceptScore W1519270045C2776714187 @default.
- W1519270045 hasConceptScore W1519270045C2776823063 @default.
- W1519270045 hasConceptScore W1519270045C2777425892 @default.
- W1519270045 hasConceptScore W1519270045C2778525890 @default.
- W1519270045 hasConceptScore W1519270045C2779281246 @default.
- W1519270045 hasConceptScore W1519270045C45197812 @default.
- W1519270045 hasConceptScore W1519270045C55493867 @default.
- W1519270045 hasConceptScore W1519270045C71240020 @default.
- W1519270045 hasConceptScore W1519270045C71924100 @default.
- W1519270045 hasConceptScore W1519270045C84393581 @default.
- W1519270045 hasConceptScore W1519270045C98274493 @default.
- W1519270045 hasIssue "8A" @default.
- W1519270045 hasLocation W15192700451 @default.
- W1519270045 hasOpenAccess W1519270045 @default.
- W1519270045 hasPrimaryLocation W15192700451 @default.
- W1519270045 hasRelatedWork W1966583389 @default.
- W1519270045 hasRelatedWork W1976450327 @default.
- W1519270045 hasRelatedWork W1977870111 @default.
- W1519270045 hasRelatedWork W2016647631 @default.
- W1519270045 hasRelatedWork W2020390064 @default.
- W1519270045 hasRelatedWork W2077998387 @default.
- W1519270045 hasRelatedWork W2126797993 @default.
- W1519270045 hasRelatedWork W2133339247 @default.
- W1519270045 hasRelatedWork W2157280939 @default.
- W1519270045 hasRelatedWork W2412177436 @default.
- W1519270045 hasVolume "39" @default.
- W1519270045 isParatext "false" @default.
- W1519270045 isRetracted "false" @default.
- W1519270045 magId "1519270045" @default.
- W1519270045 workType "article" @default.